| h-fde8ac75360e | A tau PTM barcode gates trans-synaptic templating | 0.74 | 0.71 | MAPT | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260412-094623-bb7e1c4f |
| h-69919c49 | PARP1 Inhibition Therapy | 0.74 | 0.50 | PARP1 | promoted | 2026-04-02 | sda-2026-04-01-gap-006 |
| h-seaad-v4-5a7a4079 | SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy D | 0.74 | 0.62 | SIRT3 | debated | 2026-04-03 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-0c2927c851 | H2: Impaired Autophagy Receptor Recruitment Traps G3BP1 Granules | 0.74 | 0.72 | TBK1, SQSTM1/p62, OPTN, NDP52 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-4c4414ad |
| h-013cc31a80 | Focused Ultrasound with Microbubble Contrast Agents for Antibody CNS Delivery | 0.74 | 0.81 | CLDN5/ZO-1 tight junction complex; KDR/VEGFR2 | proposed | 2026-04-22 | SDA-2026-04-02-gap-bbb-antibody-transport |
| h-811520b92f | AAV-PHP.eB-Mediated Microglial IGFBPL1 Expression | 0.74 | 0.72 | IGFBPL1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| h-SDA-2026-04-26-gap | Ultra-Low Physiological Replacement Dosing for Long-Term Prevention | 0.73 | 0.57 | MT1/ERK1/2 (MAPK1/3); Nrf2 (NFEL2L2); BACE1 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913 |
| h-SDA-2026-04-26-gap | Matrix Metalloproteinase-9 and TIMP-1 Ratio in Peripheral Blood as an Early Indi | 0.73 | 0.18 | MMP-9 (Matrix Metallopeptidase 9) / TIMP-1 ratio | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-7210c29bb9 | Metabolic Inflexibility Precedes Transcriptional Reprogramming (NAD+/SIRT3 Axis) | 0.73 | 0.68 | SIRT3/NAD+ salvage pathway, PGC-1α | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| h-15a8468c | TREM2 Agonism to Restore Microglial Phagocytosis Across Both Pathologies | 0.73 | 0.72 | TREM2, TYROBP (DAP12), PLCG2, SYK | promoted | 2026-04-17 | SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974 |
| h-trem2-6a46fa2c | Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Anta | 0.73 | 0.60 | TREM2, APOE, MAPT | proposed | 2026-04-05 | SDA-2026-04-02-gap-001 |
| h-a6e77292 | SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via | 0.73 | 0.72 | SGMS1, BECN1 | promoted | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260411-083737-59771b32 |
| h-1a4820f3 | Seed-Proximal Asymmetric Duplex Stability Confers lncRNA-0021/miR-6361 Binding S | 0.73 | 0.30 | miR-6361 seed-proximal binding site (lncRNA-0021 coordinates | proposed | 2026-04-17 | SDA-2026-04-16-gap-pubmed-20260410-150509-76c40dac |
| hyp-lyso-snca-548064 | SNCA Oligomer Binding to LAMP2A Cytosolic Tail Prevents TorsinA-Mediated LAMP2A | 0.73 | 0.62 | LAMP2 | active | 2026-04-28 | |
| h-c8ccbee8 | Aquaporin-4 Polarization Rescue | 0.73 | 0.68 | AQP4 | debated | 2026-04-02 | sda-2026-04-01-gap-005 |
| h-796cfd1c | SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regula | 0.73 | 0.75 | SMPD1 | promoted | 2026-04-16 | SDA-2026-04-15-gap-debate-20260410-112819-e40e0fa2 |
| h-bb518928 | Senescence-Associated Myelin Lipid Remodeling | 0.73 | 0.30 | PLA2G6/PLA2G4A | debated | 2026-04-02 | sda-2026-04-01-gap-013 |
| h-var-f354525002 | Selective Neutral Sphingomyelinase-2 Inhibition Therapy | 0.73 | 0.30 | SMPD3 | promoted | 2026-04-12 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-7957bb2a | Senescence-Induced Lipid Peroxidation Spreading | 0.73 | 0.40 | GPX4/SLC7A11 | debated | 2026-04-02 | sda-2026-04-01-gap-013 |
| h-a0269f3c81 | G2019S Acts as Lysosomal Volume-Sensing Amplifier via Enhanced RAB29-Dependent R | 0.73 | 0.72 | LRRK2,RAB29 | proposed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| h-083d94e34b | Metabolic-Support Secretome Dysfunction | 0.73 | 0.75 | HIF1A; SLC16A2 (MCT2); LDHA | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-170057-a2f72fd8-debate |
| h-8254c04dfd | Endosomal trafficking defects are the common upstream lesion linking APP process | 0.73 | 0.25 | SORL1, BIN1, PICALM, VPS35, APP, NTRK1 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-e849205bca |
| h-26353f7f59 | Temporal order is subtype-specific rather than universal | 0.73 | 0.76 | APOE, SORL1, NTRK1, BIN1, PICALM | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-e849205bca |
| h-08ca25f232 | H1: T-Type Calcium Channel–Driven Calcium Overload and Proteostasis Collapse | 0.73 | 0.72 | CACNA1H (Cav3.2), CAPN2, PPP2R2D | proposed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| h-9c5abf9343 | Ubiquitin-Mediated Liquid-to-Solid Transition Prevention | 0.73 | 0.78 | G3BP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041423-2d1db50c |
| h-2600483e | CYP46A1 Overexpression Gene Therapy | 0.73 | 0.85 | CYP46A1 | promoted | 2026-04-02 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-41bc2d38 | Adenosine-Astrocyte Metabolic Reset | 0.73 | 0.65 | ADORA2A | promoted | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |
| h-94ae1e45a0 | p21^Cip1 Phospho-State as Autophagy Responsiveness Predictor | 0.73 | 0.68 | CDKN1A, CDK4, CDK6, ATM, PPP1CA | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062101-724971bc |
| h-ec731b7a | Phase-Separated Organelle Targeting | 0.73 | 0.80 | G3BP1 | debated | 2026-04-02 | sda-2026-04-01-gap-009 |
| h-6ea2dc4c96 | SCFA Deficiency Drives Microglial Hyperactivation via GPR43/NF-κB Dysregulation | 0.73 | 0.82 | GPR43 (FFAR2), GPR41 (FFAR3), HDAC3, RELA (NF-κB p65) | debated | 2026-04-26 | SDA-2026-04-26-gap-20260425-225305 |
| h-3f4cb83e0c | Selective LXRβ agonists restore ABCA1/ABCG1 expression and APOE lipidation in AP | 0.73 | 0.78 | NR1H2 (LXRβ), ABCA1, ABCG1 | proposed | 2026-04-22 | SDA-2026-04-04-gap-apoe4-lipid-metabolism |
| h-54c6dd37ce | TFEB/TFE3 Parallel Activation Drives Coordinated Organelle Clearance via CLEAR N | 0.73 | 0.70 | TFEB (TFEB), TFE3 (TFE3), mTORC1 (MTOR) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062132-e71b3ef7 |
| h-84808267 | Synthetic Biology BBB Endothelial Cell Reprogramming | 0.73 | 0.60 | TFR1, LRP1, CAV1, ABCB1 | debated | 2026-04-02 | sda-2026-04-01-gap-008 |
| h-a1b56d74 | Metabolic Switch Targeting for A1→A2 Repolarization | 0.73 | 0.55 | HK2 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |
| h-3616325a | Microglial TREM2-Complement Axis Modulation | 0.73 | 0.80 | TREM2 and C3 | promoted | 2026-04-04 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-98b431ba | TFAM overexpression creates mitochondrial donor-recipient gradients for directed | 0.73 | 0.60 | TFAM | debated | 2026-04-02 | sda-2026-04-01-gap-v2-89432b95 |
| h-8fe389e8 | Astrocyte-Mediated Neuronal Epigenetic Rescue | 0.73 | 0.65 | HDAC | debated | 2026-04-02 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| h-SDA-2026-04-26-gap | Calcium-Dependent S100B Release from Astrocyte End-Feet as an Early Signal of As | 0.72 | 0.49 | S100B (S100 Calcium Binding Protein B) | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-6f6c9d3c | TDP-43 condensation thermodynamics as a therapeutic target and biomarker for nuc | 0.72 | 0.72 | TARDBP (TDP-43 protein); IPO4/IP09 (nuclear import receptors | proposed | 2026-04-26 | SDA-2026-04-10-gap-debate-20260410-075000-7396040a |
| h-5d943bfc | Proteostasis Enhancement via APOE Chaperone Targeting | 0.72 | 0.65 | HSPA1A | proposed | 2026-04-03 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-b9f5438c | TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimination Through Type I | 0.72 | 0.60 | TBK1 | proposed | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071 |
| h-8a244611 | Context-Dependent Cx43 Modulation Based on Disease Stage | 0.72 | 0.52 | GJA1 (Cx43) - context-dependent | promoted | 2026-04-13 | SDA-2026-04-12-gap-debate-20260410-113038-57244485 |
| h-var-5e33600319 | Cortico-Striatal Synchrony Restoration via NMDA Modulation | 0.72 | 0.78 | GRIN2B | proposed | 2026-04-12 | SDA-2026-04-03-26abc5e5f9f2 |
| h-99b4e2d2 | Interfacial Lipid Mimetics to Disrupt Domain Interaction | 0.72 | 0.68 | APOE | debated | 2026-04-02 | sda-2026-04-01-gap-010 |
| h-5706bbd7 | Circadian Rhythm Entrainment of Reactive Astrocytes | 0.72 | 0.50 | BMAL1 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |
| h-8d270062 | Sleep Spindle-Synaptic Plasticity Enhancement | 0.72 | 0.45 | CACNA1G | debated | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |
| h-a1552ac3 | LXRβ-Selective Agonism as a Precision Therapeutic for APOE4-Driven Myelin Defici | 0.72 | 0.72 | NR1H2 (LXRβ) | promoted | 2026-04-15 | SDA-2026-04-14-gap-pubmed-20260410-193244-89904941 |
| h-3a901ec3 | Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation | 0.72 | 0.72 | GJA1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-72c719461c | C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD | 0.72 | 0.88 | C9orf72 | proposed | 2026-04-26 | test-hypothesis-fixtures-v1 |
| h-51302631b4 | APOE4-driven pericyte injury/senescence is an upstream driver of early BBB break | 0.72 | 0.78 | APOE4, LRP1, PPIA, MMP9, PDGFRB | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-de5dfc4391 |